DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5516f7/the_future_of_opht) has announced the addition of the "The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets" report to their offering.
The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets, provides in-depth analysis of the unmet needs, drivers and barriers that impact the global ophthalmology therapeutics market. The report analyzes the ophthalmology markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive profiling for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Ophthalmology Markets Like Glaucoma Face Generic Erosion While Macular Degeneration and Edema Experience Healthy Growth
The authors have found that the global ophthalmology market will grow at a moderate rate due to the impact of generic erosion in some markets such as glaucoma and allergic conjunctivitis.
Ophthalmology Therapeutics Market, Global, Market Share by Geography, 2009 and 2016
However, the unmet need in the macular degeneration and macular edema markets make the ophthalmology market attractive despite generic erosion. The attractiveness of the macular degeneration and macular edema markets is evident from the considerable amount of research and development activity for these indications. The major factor driving the growth of the market is the rising awareness about the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools and an increase in the prevalence of diabetes. The expiry of blockbuster drugs patents and increasing pressure from cheap off-label products in some markets will be the key restraints for the market.
The entry of generics will cause glaucoma's market share to shrink. The macular degeneration and macular edema markets will eat into glaucoma's share. The share of the market generated by allergic conjunctivitis therapies, which includes a considerable number of generics, will remain the same in 2016. Due to the extensive presence of generics in the market, allergic conjunctivitis companies will take steps to improve the revenue potential of their drugs. The Rx to OTC switch is one of the strategies that can be leveraged at the right time to increase revenue potential. In addition, strategies such as branded generics will be increasingly used in the ophthalmology market.
Key Topics Covered:
- 1 TOC
- 2 Global Ophthalmology Therapeutics Market: Introduction
- 3 Global Ophthalmology Therapeutics Market: Market Overview
- 4 Global Ophthalmology Therapeutics Market: Therapeutic Landscape
- 5 Global Ophthalmology Therapeutics Market: Geographical Landscape
- 6 Global Ophthalmology Therapeutics Market: Pipeline Analysis
- 7 Global Ophthalmology Therapeutics Market: Competitive Landscape
- 8 Global Ophthalmology Therapeutics Market: Strategic Consolidations
- 9 Global Ophthalmology Therapeutics Market: Appendix
- List of Tables
- List of Figures
- Allergan, Inc.
- Alcon, Inc.
- Novartis AG
- Merck & Co Inc
For more information visit http://www.researchandmarkets.com/research/5516f7/the_future_of_opht